In the course of the ALS development program, however, dexpramipexole was observed to produce a significant and targeted depletion of eosinophils in the blood of ALS patients 4. Eosinophils are ...

--(BUSINESS WIRE)--Holoclara, a biotechnology company pioneering the development of worm-derived therapies for allergic and autoimmune disorders, today announced the selection of eosinophilic ...

Leerink Partners analyst Thomas Smith has reiterated their neutral stance on ALLK stock, giving a Hold rating on January 27.Invest with ...